Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Exact Sciences Corporation
- Study ID
- NCT03662204
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Blood Sample Collection — OTHERSubjects participating in the study will have blood drawn at enrollment.
Study Details
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
Key Dates
- First listed
- Sep 7, 2018
- Start date
- Aug 23, 2018
- Status verified
- Aug 2022
- Primary completion
- Mar 31, 2022
- Completion
- Mar 31, 2022
Study Design
- Enrollment
- 5,133 participants (actual)
Arms
- Arm: BreastSubjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: LungSubjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: ColorectalSubjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: ProstateSubjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: BladderSubjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: UterineSubjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: Kidney & Renal PelvisSubjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: PancreaticSubjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: LiverSubjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: StomachSubjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: OvarianSubjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
- Arm: EsophagealSubjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Primary Outcome Measure
Biomarker Evaluation [ Time Frame: Point in time (one day) blood collection at enrollment ]
Locations (119)
Find similar trials in Phoenix, AZ
Nationwide
Bladder cancer trialsBreast cancer trialsColorectal cancer trialsEsophageal cancer trialsKidney cancer trialsLiver cancer trialsLung cancer trialsOvarian cancer trialsPancreatic cancer trialsProstate cancer trialsGastric cancer trialsEndometrial cancer trialsOncology trialsUrology trialsBreast oncology trialsWomen's health trialsGI oncology trialsHepatology trialsLung oncology trialsLung disease trialsGynecologic oncology trialsProstate oncology trialsMen's health trials
By condition
By specialty
Related Studies
- Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland